Performance Validation of Three Scoring Systems for the Prediction of Thrombotic Microangiopathy Due to Severe ADAMTS13 Deficiency and the Response to Therapeutic Plasma Exchange: First Study in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The BENTLEY score (B-S), French thrombotic microangiopathy (TMA) Reference Center score (FTMA-S), and PLASMIC score (PLASMIC-S) have been developed for TMA diagnostic prediction. We retrospectively validated their predictive performances in patients with severe (<10%) disintegrin and metalloprotease with thrombospondin type 1 motif, member 13 (ADAMTS13) deficiency in terms of the risk of TMA and response to therapeutic plasma exchange (TPE). Methods: The predictive performances of the three scoring systems were compared in 145 patients with suspected TMA who underwent ADAMTS13 activity tests between January 2014 and September 2022. The response to TPE and mortality in TMA-positive patients were compared after risk stratification, using the Mann–Whitney U and Fisher’s exact tests. Results: The PLASMIC-S, FTMA-S, and B-S showed area under the curve values of 0.820, 0.636, and 0.513, respectively, for predicting TMA positivity in high-risk patients. The PLASMIC-S showed higher sensitivity (81.8%), negative predictive value (91.2%), positive predictive value (PPV; 66.7%), and accuracy (82.1%) than the FTMA-S (72.7%, 82.1%, 41.0%, and 60.0%, respectively) and B-S (4.6%, 70.2%, 50.0%, and 69.7%, respectively). The PLASMIC-S also showed higher specificity than the FTMA-S (82.2% vs. 54.5%). The modified PLASMIC-S, including lactate dehydrogenase/upper limit of normal ratios, increased the specificity, PPV, and accuracy to 97.0%, 92.3%, and 92.4%, respectively. In TMA-positive patients, high risk assessed by the PLASMIC-S predicted higher platelet recovery rates and less TPE sessions required for recovery than for those assessed at low-to-intermediate risk. Conclusions: PLASMIC-S is the preferred scoring system for detecting patients with TMA positivity and for prognosis before confirmation of ADAMTS13 activity.
Abstract
Background: The BENTLEY score (B-S), French thrombotic microangiopathy (TMA) Reference Center score (FTMA-S), and PLASMIC score (PLASMIC-S) have been developed for TMA diagnostic prediction. We retrospectively validated their predictive performances in patients with severe (<10%) disintegrin and metalloprotease with thrombospondin type 1 motif, member 13 (ADAMTS13) deficiency in terms of the risk of TMA and response to therapeutic plasma exchange (TPE). Methods: The predictive performances of the three scoring systems were compared in 145 patients with suspected TMA who underwent ADAMTS13 activity tests between January 2014 and September 2022. The response to TPE and mortality in TMA-positive patients were compared after risk stratification, using the Mann–Whitney U and Fisher’s exact tests. Results: The PLASMIC-S, FTMA-S, and B-S showed area under the curve values of 0.820, 0.636, and 0.513, respectively, for predicting TMA positivity in high-risk patients. The PLASMIC-S showed higher sensitivity (81.8%), negative predictive value (91.2%), positive predictive value (PPV; 66.7%), and accuracy (82.1%) than the FTMA-S (72.7%, 82.1%, 41.0%, and 60.0%, respectively) and B-S (4.6%, 70.2%, 50.0%, and 69.7%, respectively). The PLASMIC-S also showed higher specificity than the FTMA-S (82.2% vs. 54.5%). The modified PLASMIC-S, including lactate dehydrogenase/upper limit of normal ratios, increased the specificity, PPV, and accuracy to 97.0%, 92.3%, and 92.4%, respectively. In TMA-positive patients, high risk assessed by the PLASMIC-S predicted higher platelet recovery rates and less TPE sessions required for recovery than for those assessed at low-to-intermediate risk. Conclusions: PLASMIC-S is the preferred scoring system for detecting patients with TMA positivity and for prognosis before confirmation of ADAMTS13 activity.
참고문헌 (33)
- George JN, "Syndromes of thrombotic microangiopathy", N Engl J Med, 371, pp.654~666 (2014)
- Bendapudi PK, "Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies : a cohort study", Lancet Haematol, 4, pp.e157~64 (2017)
- Bendapudi PK, "Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies : the experience of the Harvard TMA Research Collaborative", Br J Haematol, 171, pp.836~844 (2015)
- Hassan S, "The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies : results from the UK TTP Registry", Br J Haematol, 171, pp.830~835 (2015)
- Moake JL, "Unusually large plasma factor VIII : von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura", N Engl J Med, 307, pp.1432~1435 (1982)
- Fujikawa K, "Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family", Blood, 98, pp.1662~1666 (2001)
- Gerritsen HE, "Partial amino acid sequence of purified von Willebrand factor-cleaving protease", Blood, 98, pp.1654~1661 (2001)
- Tsai HM, "Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura", N Engl J Med, 339, pp.1585~1594 (1998)
- Furlan M, "von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome", N Engl J Med, 339, pp.1578~1584 (1998)
- Amorosi EL, "Thrombotic thrombocytopenic purpura : report of 16 cases and review of the literature", Medicine, 45, pp.139~160 (1966)
- Bell WR, "Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients", N Engl J Med, 325, pp.398~403 (1991)
- Rock GA, "Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian apheresis study group", N Engl J Med, 325, pp.393~397 (1991)
- Zheng XL, "ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura", Annu Rev Med, 66, pp.211~225 (2015)
- Zheng XL, "Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura", Blood, 103, pp.4043~4049 (2004)
- Vesely SK, "ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome : relation to presenting features and clinical outcomes in a prospective cohort of 142 patients", Blood, 102, pp.60~68 (2003)
- Veyradier A, "Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies : a study of 111 cases", Blood, 98, pp.1765~1772 (2001)
- Coppo P, "Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement", Medicine, 83, pp.233~244 (2004)
- Coppo P, "Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies : the French TMA reference center experience", PLoS One, 5, pp.e10208~ (2010)
- Shah N, "Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura(TTP)", Br J Haematol, 163, pp.514~519 (2013)
- Scully M, "Regional UK TTP registry : correlation with laboratory ADAMTS 13 analysis and clinical features", Br J Haematol, 142, pp.819~826 (2008)
- Mariotte E, "Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency(thrombotic thrombocytopenic purpura) : a cross-sectional analysis of the French national registry for thrombotic microangiopathy", Lancet Haematol, 3, pp.e237~45 (2016)
- Li A, "Treatment with or without plasma exchange for patients with acquired thrombotic microangiopathy not associated with severe ADAMTS13 deficiency : a propensity score-matched study", Transfusion, 56, pp.2069~2077 (2016)
- Connell NT, "Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura", Transfusion, 56, pp.354~359 (2016)
- Bentley MJ, "The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange", Transfusion, 50, pp.1654~1664 (2010)
- Bentley MJ, "Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort", Vox Sang, 105, pp.313~318 (2013)
- Li A, "External validation of the PLASMIC score : a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment", J Thromb Haemost, 16, pp.164~169 (2018)
- Bendapudi PK, "Clinical scoring systems in thrombotic microangiopathies", Semin Thromb Hemost, 43, pp.540~548 (2017)
- Liu A, "Reduced sensitivity of PLASMIC and French scores for the diagnosis of thrombotic thrombocytopenic purpura in older individuals", Transfusion, 61, pp.266~273 (2021)
- Zhao N, "A modified PLASMIC score including the lactate dehydrogenase", the upper limit of normal ratio more accurately identifies Chinese thrombotic thrombocytopenic purpura patients than the original PLASMIC score, 2020, pp.35, 79~85
- Patriquin CJ, "Plasma exchange in TTP : to taper or not to taper", Transfusion, 60, pp.1647~1648 (2020)
- Hanley JA, "A method of comparing the areas under receiver operating characteristic curves derived from the same cases", Radiology, 148, pp.839~843 (1983)
- Fage N, "Proteinuria increases the PLASMIC and French scores performance to predict thrombotic thrombocytopenic purpura in patients with thrombotic microangiopathy syndrome", Kidney Int Rep, 7, pp.221~231 (2021)
- Kato S, "Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity", Transfusion, 46, pp.1444~1452 (2006)
